|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 13, 2016 ) Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina) , pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.
Report Highlights:
The report Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 5, 43 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 25 and 4 molecules, respectively.Atherosclerosis.
Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from
The report proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/atherosclerosis-pipeline-review-h2-2016
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular) .
- The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001461486/sample
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Companies profiles
Ache Laboratorios Farmaceuticos S/A
advanceCor GmbH
AFFiRiS AG
Akcea Therapeutics Inc
Amgen Inc.
Arisaph Pharmaceuticals, Inc.
ARMO Biosciences, Inc.
Artery Therapeutics, Inc.
Athera Biotechnologies AB
Cardax, Inc.
Cerenis Therapeutics Holding SA
ChemoCentryx, Inc.
CohBar, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
DoNatur GmbH
Dybly AG
Ask for Discount at
http://www.reportsweb.com/inquiry&RW0001461486/discount
List of Table
Atherosclerosis - Pipeline by LipimetiX Development Inc, H2 2016 59
Atherosclerosis - Pipeline by Merck & Co., Inc., H2 2016 60
Atherosclerosis - Pipeline by Omeros Corporation, H2 2016 61
Atherosclerosis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 62
Atherosclerosis - Pipeline by Resverlogix Corp., H2 2016 63
Atherosclerosis - Pipeline by The Medicines Company, H2 2016 64
Atherosclerosis - Pipeline by Therapix Biosciences Ltd., H2 2016 65
Atherosclerosis - Pipeline by Tolerys SA, H2 2016 66
Atherosclerosis - Pipeline by Unity Biotechnology, Inc., H2 2016 67
Atherosclerosis - Pipeline by Vascular Biogenics Ltd., H2 2016 68
Atherosclerosis - Pipeline by Vericel Corporation, H2 2016 69
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
